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Arsenic trioxide (ATO)Aberrant expression of the proto-oncogene EVI1 (ecotropic virus integration site1) has been implicated not
only in myeloid or lymphoid malignancies but also in colon, ovarian and breast cancers. Despite its impor-
tance in oncogenesis, the regulatory factors and mechanisms that potentiate the function of EVI1 and its con-
sequences are partially known. Here we demonstrated that EVI1 is post-translationally modiﬁed by SUMO1
at lysine residues 533, 698 and 874. Although both EVI1 and SUMO1 were found to co-localize in nuclear
speckles, the sumoylation mutant of EVI1 failed to co-localize with SUMO1. Sumoylation abrogated the
DNA binding efﬁciency of EVI1 and also affected EVI1 mediated transactivation. The SUMO ligase PIASy
was found to play a bi-directional role on EVI1, PIASy enhanced EVI1 sumoylation and augmented
sumoylated EVI1 mediated repression. PIASy was also found to interact with EVI1 and impaired EVI1 tran-
scriptional activity independent of its ligase activity. Arsenic trioxide (ATO) known to act as an antileukemic
agent for acute promyelocytic leukemia (APL) not only enhanced EVI1 sumoylation but also enhanced the
co-localization of EVI1 and SUMO1 in nuclear bodies distinct from PML nuclear bodies. ATO treatment also
affected the Bcl-xL protein expression in EVI1 positive cell line. Thus, the results showed that arsenic treat-
ment enhanced EVI1 sumoylation, deregulated Bcl-xL, which eventually may induce apoptosis in EVI1 posi-
tive cancer cells. The study for the ﬁrst time explores and reports sumoylation of EVI1, which plays an
essential role in regulating its function.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Transcriptional activation of human EVI1 gene occurs in myeloid
neoplasm as a consequence of chromosomal translocation and inser-
tion involving chromosome band 3q26, where the gene is located.
There are seven splice variants of EVI1 (Homo sapiens) reported in
NCBI which differs in 5′UTR region of the nucleotide sequence. Ab-
normal expression of EVI1 has also been demonstrated in patients
with a normal karyotype, suggesting that activation of the EVI1 gene
may occur via other mechanisms as well. Studies reveal that EVI1
may be over expressed in solid tumors which can affect the disease
progression or sensitivity to chemotherapy [1–3]. Ectopic expression
of EVI1 in bone marrow (BM) progenitors lead to an alteration in
granulopoiesis and a block in erythropoiesis in response to cytokines
in vitro whereas in ovarian epithelial cells, only short term expression
of EVI1 increased proliferation however long term expression strong-
ly reduced growth and/or survival [4,5]. Recent studies point to the
fact that EVI1 controls the function of a number of genes some of whichco Square, Bhubaneswar, Orissa
0728.
ils.res.in (S. Chakraborty).
rights reserved.are deciphered and/or the function of EVI1 is dictated by a group of spe-
ciﬁc regulators that post-translationally modify EVI1. Post-translational
modiﬁcations on a protein constitute complex regulatory program that
transduces molecular information through signaling pathways. Similar
cascade of eventsmay occur in the process of post-translationalmodiﬁca-
tion of EVI1 which needs to be investigated.
SUMO (small ubiquitin-likemodiﬁer)modiﬁcation is a covalent pro-
tein modiﬁcation mediated by a set of sumoylation pathway enzymes.
SUMO covalently attaches to a wide variety of proteins, through an en-
zymatic cascade on lysine residues at consensus sequence ΨKXE/D
(where Ψ is a large hydrophobic amino acid, K is the target lysine, X
is any amino acid and E/D is glutamic/aspartic acid). Sumoylation
increases molecular weight of its target protein by 15–18 kDa in
SDS-PAGE gel. In proteins having more than one sumoylation site, an
increase in the molecular mass is expected depending on the number
of the sites. Multiple bands are also observed which corresponds to
different sumoylation states of the protein. Sumoylation can modulate
protein function by stabilizing it, changing its subcellular localization,
helping it with protein–protein and/or protein–DNA interaction [6–13].
Indeed several transcription factors, such as p53, SP3, c-Jun, c-Myb,
MEL1S, transcriptional co-activator such as GRIP1, viral protein IE2-p86
and various nuclear receptors like AR have recently been shown to be a
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negative inﬂuence on the transcriptional activity of several targets
[14–18]. Pathologies including prostate cancer, breast cancer and several
neurological disorders like Parkinson's, Alzheimer's, and Huntington's
diseases have been reported to be associated with irregular patterns of
sumoylation [19,20]. Arsenic trioxide (ATO), a potent anti-cancer agent
directly binds to PML and degrades PML-RARα as well as PML through
SUMO dependent polyubiquitination leading to apoptosis of APL cells
[21]. Low doses of ATO induce partial differentiation whereas higher
dose causes apoptosis in APL cells. ATO inhibits cell growth and induces
apoptosis in several cancer cell lines [22,23].
Previously we and others have reported that acetylated and
deacetylated form of EVI1 can divergently regulate various functions
of EVI1 by inﬂuencing Bcl-xL and GATA-2 transcriptional activity
[24,25]. Our present observation reveals that EVI1 is modiﬁed by
SUMO1 at lysine residues 533, 698 and 874. Sumoylation was found
to negatively regulate the transactivation function and DNA binding
afﬁnity of EVI1. PIASy was found to be a new interacting partner and
a negative regulator of EVI1 which also enhanced EVI1 sumoylation.
ATO treatment in ovarian carcinoma (SKOV3) cells not only increased
sumoylation of EVI1 but also enhanced the co-localization rate of EVI1
and SUMO1 in nuclear speckles other than PML nuclear bodies. The
study reveals the role of ATO in enhancing EVI1 sumoylation, and that
a marked decrease in Bcl-xL expression supports the mechanism in-
volved in ATO induced apoptosis in cancer cells.
2. Materials and methods
2.1. Plasmids
CMV-ﬂag-EVI1 was cloned from EVI1-myc as described previously
(the ﬁrst methionine of EVI1 was disrupted and the construct utilizes
the start codon of ﬂag tag) [24]. Full length EVI1 was cloned as
pGEX-ﬂag-EVI1 from CMV-ﬂag-EVI1 into pGEX-6P-1-ﬂag (pGEX-6P-
1-ﬂag was constructed by inserting the ﬂag tag epitope sequence in
BamHI and SalI sites within the multiple cloning site of pGEX-6P-1).
CMV-Ubc9-ﬂag was cloned from pTET23a-Ubc9 (provided by Dr. F.
Melchior, Heidelberg University, Germany) into EcoRV and SalI of
CMV-ﬂag-NLS. pCDNA3-SUMO1-HA was a kind gift from Dr. R. Hay
(University of Dundee, Scotland, UK). PIASy-ﬂag was provided by Dr.
R. Grosschedl (Max Planck Institute for Immunobiology and Epige-
netics, Germany). Reporter plasmid; pGL2-Bcl-xL promoter (fragment
containing the EVI1 binding site cloned in pGL2 is from−3102 to +98
taking transcription start site as 1) or pGL4.10-SIRT1 promoter (covers
2.4 kb upstream from the start codon of SIRT1) and Renilla luciferase
plasmid; pRL-TK are described previously [24,26]. SUMO–Ubc9 (Su Ub)
fusion plasmid was provided by Dr. Jin-Hyun Ahn (Samsung Biomedical
Research Institute, Korea) [27]. Su–Ub fusion plasmid was generated by
cloning SUMO and Ubc9 together with a linker. As per the literature
the construct enhanced the sumoylation efﬁciency of proteins having
SIM (SUMO interacting motif). Although EVI1 doesn't have a known
SIM sequence in its coding region, we found it to be equally efﬁcient to
Ubc9 to promote sumoylation of EVI1.
2.2. Site directed mutagenesis
The point mutants used in the study were generated by inserting
mutation into CMV-ﬂag-EVI1 and pGEX-ﬂag-EVI1 by PCR cloning
method using primers designed for introducing speciﬁed mutations
(lysine to arginine). All the plasmids were sequenced to validate the
presence of desired mutations.
2.3. Cell culture and transfection
HEK293T (human embryonic kidney) and SKOV3 (ovarian cancer)
cell lines were maintained in Dulbecco's modiﬁed Eagles medium(DMEM, Invitrogen, USA) supplemented with 10% heat inactivated
fetal bovine serum (Invitrogen, USA) in 37 °C, 5% CO2 incubator.
HEK293T cells were transfected by calcium phosphate precipitation
method with various plasmid combinations as indicated in the ﬁgures.
Control-siRNA and SUMO1-siRNA (Santa Cruz, CA) transfection in
SKOV3 cell line was done using Icafectin siRNA transfection reagent
(Eurogentec, Belgium).
2.4. Antibodies
Antibodies that were used in the assays include, mouse monoclonal
anti-ﬂag (M2) antibody (Sigma, USA), anti-EVI1 and anti-EVI1 (C50E12)
(Cell Signaling Technology, USA), anti-HA (3F10) (Roche Applied Science,
Germany), anti-SUMO1 (from Active Motif kit, USA and Santa Cruz, CA),
anti-SUMO1 (D-11) and anti-PML (PG-M3) (Santa Cruz, CA) and anti-
Bcl-xL (Imgenex, India). Anti-mouse, anti-rabbit and anti-rat secondary
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Alexa-488 and alexa-594 conjugated anti-rabbit, anti-mouse and
anti-rat were purchased from Invitrogen, USA.
2.5. Puriﬁcation and expression of pGEX-EVI1-ﬂag and mutants in
Escherichia coli
For production of EVI1-ﬂag and mutant proteins by GST pull down
assay, BL21 competent cells were transformed with pGEX-ﬂag-EVI1
and themutants. Transformed cells were grown and protein expression
was induced with IPTG (Sigma, USA). Cells were harvested and lysed in
phosphate buffer saline supplemented with Triton-X (Sigma, USA) and
protease inhibitor (Sigma, USA). Lysates were incubated with 50 μl of
GST-tagged sepharose beads (GE Healthcare, UK) for 2 h at 4 °C. Pro-
teins were eluted by incubating the beads in cleavage buffer with
preScission protease (GE healthcare, UK).
2.6. In vitro sumoylation assay
The assay was performed using GST puriﬁed protein and in vitro
sumoylation assay kit (Active Motif, USA) which consists of E1 activat-
ing enzyme, E2 conjugating enzyme, SUMO1/SUMO1-mut proteins,
protein buffer and sumoylation buffer.
2.7. Immunoblot analysis and immunoprecipitation
For in vivo sumoylation assays, HEK293T cells seeded in 6 cm cell
culture dish were transfected with 3 μg of CMV-ﬂag-EVI1, 5 μg of
pCDNA3-SUMO1-HA, 3 μg of Su Ub (SUMO–Ubc9 fusion plasmid)/
CMV-Ubc9-ﬂag, with or without 3 μg of PIASy-ﬂag. The DNA concen-
tration was equalized by adding equal concentration of CMV-ﬂag vec-
tor. EVI1 positive SKOV3 cells or transiently transfected HEK293T
cells were washed with phosphate buffer saline, lysed in 2× sample
buffer containing 20 mM N-ethylmaleimide (NEM; sumoylation pro-
tease inhibitor) and boiled for 10 min. After centrifugation superna-
tants were subjected to SDS-PAGE and analyzed by immunoblotting
using indicated antibodies.
For co-immunoprecipitation assay, HEK293T cells grown in 10 cm
cell culture plates were transfected with 7 μg each of EVI1-myc and
PIASy-ﬂag. For immunoprecipitation experiments, HEK293T cells
transfected with indicated plasmids mentioned in ﬁgure were lysed
in lysis buffer (25 mM Tris–Cl; pH 7.5, 150 mM NaCl, 1% NP-40)
supplemented with protease inhibitor (Sigma, USA) and cleared by
centrifugation. Lysates were precleared with protein A/G beads (GE
Healthcare, UK). Precleared lysates were incubated with indicated an-
tibodies for 2 h at 4 °C followed by overnight incubation with protein
A/G beads. Immunoprecipitates collected on the beads were washed
three times with IP wash buffer (50 mM Tris–Cl; pH 8.0, 150 mM
NaCl, 0.1% NP-40, 1 mM EDTA) supplemented with protease inhibitor
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ple buffer and analyzed by SDS-PAGE and immunoblotting.
2.8. Indirect immunoﬂuorescence assay
SKOV3 or HEK293T cells were cultured on gelatin coated coverslips.
HEK293T cells were transiently transfected with 3 μg EVI1-ﬂag/EVI1
(3KR)-ﬂag (lysine to arginine mutation at position 533, 698 and 874
in EVI1) and 5 μg SUMO1-HA. After 36 h, cells were washed in cold
1× PBS, ﬁxed with 4% paraformaldehyde (Sigma, USA) and perme-
abilized with methanol:acetone (Qualigen, USA). Cells were stained
with primary antibodies for 1 h and Alexa ﬂuor tagged secondary anti-
bodies for 40 min. Cells were washed and stained with DAPI (Sigma,
USA), mounted on glass slides with an antifade mounting reagent
(Invitrogen, USA). The slides were visualized under a laser scanning
confocal microscope (Leica, Germany) using Argon-488, He–Ne-594
and 405 solid state laser.
2.9. Reporter gene assay
HEK293T cells plated in sixwell platewere co-transfectedwith indi-
cated plasmids in the ﬁgures at a concentration of 1 μg of pGL2-Bcl-xL/
pGL4.10-SIRT1 promoter, 1 μg each of CMV-ﬂag, EVI1-ﬂag/EVI1 (3KR)-
ﬂag, PIASy-ﬂag and 2 μg of SUMO1-HAalongwith 0.2 μg of Renilla lucif-
erase plasmid; pRL-TK per well. After 24 h, cells were assayed with a
Dual luciferase assay system (Promega, USA) and luciferase activity
was determined by luminometer (Glomax 20/20, Promega, USA) as
per manufacturer's instruction.
2.10. Chromatin immunoprecipitation (ChIP) assay
ChIP assaywas performed in HEK293T cells transfectedwith EVI1 and
Su Ub (SUMO–Ubc9 fusion plasmid) or SKOV3 cells with control-siRNA
and SUMO1-siRNA using Quik ChIP kit (Imgenex, India) as described pre-
viously [24]. EVI1 protein was immunoprecipitated with EVI1 (C50E12)
antibody (Cell Signaling Technology, USA). The promoter-speciﬁc primers
ﬂanking the binding site used for the PCR were: Bcl-xL-F AGGGTA
AATGGCATGCATATTAA and Bcl-xL-R TTATAATAGGGATGGGCTCAACCA
(amplicon size-170 bp).
2.11. Real-time quantitative PCR
Total RNA was extracted from control-siRNA and SUMO1-siRNA
transfected SKOV3 cells by using TRIzol reagent (Invitrogen, CA). SYBR
green master mix (Roche Applied Science, Germany) was used for the
real time PCR (RQ-PCR) on Opticon 2.0 (MJ Research, USA). Fold change
of target gene relative to β-actin was calculated by 2¯ΔΔCt where
ΔΔCt = (Ct Bcl-xL- Ct β-actin for SKOV3 cells) − (Ct Bcl-xL- Ct
β-actin for SUMO1-siRNA transfected SKOV3 cells). PCR primers were
designed from the Bcl-xL mRNA reference sequence, NM_138578.1:
Bcl-xL forward-GCCACTTACCTGAATGACCAC, Bcl-xL reverse-TGGATG
GTCAGTGTCTGGT (amplicon size-210 bp). P value was determined by
using the GraphPad Prism software, version 5.01.
2.12. Arsenic treatment
ATO (Sigma, USA) was dissolved in 1.65 M NaOH to make 50 mM
stock solution. 1 μM solution was prepared by serial dilution in
DMEM media and cells were treated for 1 h.
2.13. Statistical analysis
All the statistical comparisons were conducted by using GraphPad
Prism version 5.01 (Graph Pad software). Data presented as mean
value ± s.e. for experiments performed in replicates. A P value less
than 0.05 is considered to be signiﬁcant. Statistical analysis for allthe reporter gene assays was done by one way ANOVA. RQ-PCR anal-
ysis and densitometric analysis was done by unpaired t-test.
3. Results
3.1. EVI1 is sumoylated both in vitro and in vivo by SUMO1
Sumoylation is a very dynamic process and it is very difﬁcult to de-
tect the modiﬁcation, ﬁrstly because only a small fraction of the total
protein is sumoylated and secondly in the cellular system several cyste-
ine proteases cleave SUMO from its target [28]. Bioinformatically, it was
predicted earlier that EVI1 is a potent target of sumoylation [14].We ini-
tially checked whether EVI1 is sumoylated by in vitro analysis. GST pu-
riﬁed EVI1 was incubated with E1 activating enzyme, E2 conjugating
enzyme and SUMO1 or SUMO1 (mut). The samples were run in 6%
SDS-PAGE and analyzed by immunoblotting with anti-ﬂag antibody.
Sumoylation of a protein on a western blot is inferred by the presence
of a slowmigrating higher size band. A band of slower mobility was ob-
served in EVI1-ﬂag when incubated with SUMO1 (Fig. 1A, lane 2,
marked by an arrow) and was absent in others. To determine whether
sumoylation of EVI1 also occurs in vivo, HEK293T cells transfected
with plasmids as indicated in the ﬁgure were lysed in 2× sample buffer
containing NEM. The sample was separated in SDS-PAGE and subjected
to immunoblotting with anti-ﬂag antibody. We observed higher size
bands (marked by arrows) along with the 145 kDa band of EVI1, in
lanes where EVI1 was co-transfected with Su Ub and SUMO1 (Fig. 1B,
lane 2). Lower panel shows the sumoylated EVI1 band in the same
blot, stripped and reprobed with anti-HA antibody (Fig. 1B, lane 2). En-
dogenous sumoylation of EVI1was checked in SKOV3 cell line by silenc-
ing SUMO1. Immunoblotting analysis was performed with anti-EVI1
antibody for the samples lysed in 2× sample buffer and loaded in two
different volumes in a 6% SDS-PAGE gel for 2 h in order to get a better
resolution of the separated bands and to get a proper demarcation
between sumoylated EVI1 and MDS1-EVI1 (band present above
sumoylated EVI1). An additional slow migrating band was observed in
both the lanes, but the band intensity of lane 2 was less in comparison
to lane 1, as the amount of protein lysates loaded in lane 2 was less
than lane 1 (Fig. 1C, lane1 and 2, upper panel). The higher size
sumoylated EVI1 band disappeared when the cells were transfected
with SUMO1 siRNA (Fig. 1C, lane 3, upper panel) which was further
conﬁrmed with anti-SUMO1 antibody (Fig. 1C, lower panel). Fig. 1D
shows the endogenous SUMO1 expression (upper panel) and actin
(lower panel). Thus we show that EVI1 is sumoylated both in vitro as
well as in vivo.
3.2. Lysines-533, 698 and 874 are the major sumoylation sites in EVI1
Sumoylation is known to occur at lysine(s) embedded in a con-
sensus motif ΨKXE/D [29]. Recent study also deﬁnes extended mo-
tifs for sumoylation termed as PDSM (phosphorylation dependent
sumoylation motif) and NDSM (negatively charged amino acid-
dependent sumoylationmotif) [30,31]. Examination of protein sequence
of EVI1 by SUMOplot (http://www.abgent.com/tools/sumoplot) and
SUMOsp 2.0 (http://sumosp.biocuckoo.org/online.php) revealed the
presence of core, conserved and extended SUMO motifs in EVI1 at
lys-533, 698 and874with scores equal to or above 0.85 or high threshold
and were found to be evolutionarily conserved among different species
(Fig. 2A). There are seven variants of EVI1 (H. sapiens) which differ in
their 5′UTR region. All the three sumoylation sites were also conserved
among all the seven variants of EVI1 (Fig. 2B). Interestingly, all the
three sites come under NDSM and lys-533 is a predicted PDSM site.
To determine whether the predicted sites in EVI1 are the sites of
sumoylation we generated sumoylation deﬁcient point mutants of EVI1
and checked for the sumoylation status in vitro. Single mutants of
K533R or K698R or K874R failed to completely block sumoylation, dou-
ble mutant of K533R and K698R termed as EVI1 (2KR)-ﬂag partially
Fig. 1. SUMO1 modiﬁes EVI1. (A) Puriﬁed EVI1-ﬂag protein produced from pGEX-ﬂag-EVI1 transformed BL21 competent cells by GST pull down method was subjected to
sumoylation assay in the presence of E1, E2 and SUMO1/SUMO1-mut. Proteins were resolved in 6% SDS-PAGE and visualized by immunoblotting with anti-ﬂag antibody. The mod-
iﬁed band is indicated with an arrow. (B) HEK293T cells transiently transfected with CMV-ﬂag-EVI1, Su Ub (SUMO–Ubc9 fusion plasmid) and pCDNA3-SUMO1-HA was lysed
directly in SDS gel loading buffer containing NEM. Proteins were separated in 6% SDS-PAGE gel and visualized by immunoblotting with anti-ﬂag antibody/anti-HA antibody. The
modiﬁed bands are indicated with arrows. (C) For analyzing endogenous sumoylation of EVI1, SKOV3 cells with and without SUMO1-siRNA was lysed directly in 2× sample buffer,
20 μl and 10 μl for SKOV3 and 20 μl for SUMO1 siRNA transfected SKOV3 samples were subjected to 6% SDS-PAGE gel and probed with anti-EVI1/anti-SUMO1 antibodies. (D) The
samples were re-run in 14% SDS PAGE and visualized by immunoblotting with anti-SUMO1 (for SUMO1 expression) and anti-actin antibodies (loading control).
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sines 533, 698 and 874 to arginine, termed as EVI1 (3KR)-ﬂag abolished
the slow migrating band (Fig. 2C, lane 4) which was present in the
wild type EVI1 (lane 2). Thus, EVI1 was found to be a substrate for
sumoylation at three positions, two in repression domain, as found in
several other transcription factors and one in the acidic domain [14].3.3. EVI1 and SUMO1 co-localizes in nuclear speckles
EVI1 existsmostly in a diffused patternwith approximately 5–10% of
cells showing nuclear speckles [32]. In transiently transfected HEK293T
cells and EVI1 positive SKOV3 cellswe observed approximately 5–10%of
cells with EVI1 in speckles. We found by indirect immunoﬂuorescence
assay that EVI1 co-localized with SUMO1 in nuclear speckles when
overexpressed in HEK293T cells (Fig. 3A, upper panel) as well as endog-
enously in SKOV3 cells (Fig 3A, lower panel). Scatter plot of the merged
images revealed co-localization rate equal to or above 85% and Pearson's
coefﬁcient showed a positive association between EVI1 and SUMO1.
We also checked whether sumoylation affects the localization pat-
tern of sumoylation deﬁcient EVI1 by indirect immunoﬂuorescence
assay in HEK293T cells transfected with EVI1 (3KR)-ﬂag and SUMO1-
HA. The mutant was also found to be localized in nucleus but the co-
localization of mutant EVI1 and SUMO1 was appreciably disrupted.
Scatter plot result showed a co-localization rate of 20.15% and
Pearson's coefﬁcient of 0.7636 (Fig. 3B). Thus it may be possible
that sumoylation plays a role in translocating EVI1 from diffused
form to nuclear speckles.3.4. Sumoylation of EVI1 interferes with its transcriptional activity and
DNA binding ability
Sumoylation is known to bring a diverse effect on the activity of
several transcription factors, such as; it decreases the transcriptional
activity of AR, c-Jun whereas it helps in the transactivation of Oct-4,
PAX-6, DLX3 [6,18,33–35]. EVI1 activates Bcl-xL and SIRT1 promoter
activities [24,26]. In order to test the effect of sumoylated EVI1 on
Bcl-xL promoter, reporter gene assay was performed in HEK293T cells
transfected with plasmids indicated in ﬁgure along with reporter gene
and Renilla constructs. A signiﬁcant impairment in EVI1 mediated acti-
vation was observed on Bcl-xL promoter when SUMO1 was added
(Fig. 4A, bar 3 compared to bar 2). Negative regulatory effect imposed
by sumoylation on EVI1 activitywas also observedwith SIRT1 promoter
(Fig. 4B). Expressions of EVI1 and SUMO1 are shown by western
blotting. Results obtained from reporter gene assay of EVI1 with
control-siRNA and SUMO1-siRNA showed an increase in the activity of
EVI1 when HEK293T cells were transfected with SUMO1-siRNA
(Fig. 4C, bar 4 compared to bar 2). Expressions of EVI1 and SUMO1 are
shown by immunoblotting and actin is taken as the loading control.
The results thus obtained show that sumoylation acts as a negative reg-
ulator for EVI1. In order to further validate our data, transcriptional ac-
tivity of wild type EVI1 was compared with the triple mutant EVI1
(3KR) taking Bcl-xL promoter into account. The data revealed a minor
increase in promoter activity in presence of EVI1 (3KR) (Fig. 4D, bar
4) in comparison to wild type EVI1 (Fig. 4D, bar 2). Reporter gene
assay was also performed with empty promoter vector and pGL2-
Bcl-xL together with EVI1 and EVI1 (3KR). No role of EVI1 or EVI1
Fig. 2. Lysines 533, 698 and 874 are themain acceptor sites for SUMO1 and are conserved among species. (A) The schematic diagram represents the three putative sumoylation sites present
in EVI1, two in repression domain and one in acidic domainswhich were found to be evolutionarily conserved among the different species. Table shows the scores equal to or above 0.85 or
high threshold in EVI1, generated from the prediction softwares (SUMOplot and SUMOsp 2.0). (B) Bioinformatically deduced sumoylation sites are also conserved in all the variants of EVI1.
The EVI1 sequences were obtained from theNCBI reference sequence database. (C) In vitro sumoylation assay was done by takingGST puriﬁed proteins of pGEX-ﬂag-EVI1 and triplemutant
pGEX-ﬂag-EVI1 (3KR), incubated with kit reagents and checked by immunoblotting with anti-EVI1 antibody. A line diagram represents the site of mutation in EVI1.
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Fig. 1). Since there was no signiﬁcant difference in the activity of EVI1
and EVI1 (3KR), we also checked the above by co-expressing SUMO1.
As shown earlier, SUMO1 negatively regulated the activity of wild
type EVI1 (Fig. 4D, bar 3), however it failed to deactivate EVI1-3KR ac-
tivity (Fig. 4D, bar 5) suggesting that the absence of sumoylation sites
prevent SUMO1 tomodify EVI1 and regulate its function. Similar results
were obtained with SIRT1 promoter (Fig. 4E). Protein expressions of
EVI1 and SUMO1 are shown below the bar diagrams. The above data in-
dicates that mutating sumoylation sites can modify the functions of
EVI1 and eventually can inﬂuence several downstream pathways con-
trolled by EVI1. Further, to understand the role of sumoylated EVI1 we
assessed the possible reason for sumoylation mediated negative reg-
ulation. To this end, we checked the effect of sumoylation on the DNA
binding ability of EVI1 by ChIP assay in HEK293T cells transfected with
EVI1 and Su Ub or SKOV3 cell line transfected with control-siRNA/
SUMO1-siRNA. The binding speciﬁcity of EVI1 to Bcl-xL was previously
reported by us [24]. In case of HEK293T cells there was a decrease in
DNA binding on Bcl-xL promoter when EVI1 was co-transfected with
Su Ub in comparison to only EVI1 (Fig. 4F, lane 3 and 2, left upper
panel) whereas no ampliﬁcation was observed in the only vector and
Su Ub. Right panel shows the expression of EVI1 and SuUb. EVI1 positive
SKOV3 cells were transfected with control-siRNA and SUMO1-siRNA.
Cells from the same set of experiment were taken for ChIP, real timePCR and immunoblotting experiments. In case of SKOV3, an increase in
binding of EVI1 to Bcl-xL promoter was observed in SUMO1-siRNA
transfected SKOV3 cells in comparison to control-siRNA transfected
SKOV3 cells (Fig. 4G, lanes 4 and 2, left upper panel). Left lower panel
depicts the input control. In order to accurately quantify the Bcl-xL ex-
pression at mRNA level we performed real time PCRwith RNA extracted
from the control and SUMO1-siRNA transfected cells. By down regulating
SUMO1 expression we observed almost three fold-up regulation in
Bcl-xL activity (Fig. 4H). Data was normalized to the endogenous
β-actin expression level. The protein expression of Bcl-xL in SUMO1-
siRNA transfected cells was also found to be comparatively more than
in control-siRNA transfected SKOV3 cells (right panel). Protein expres-
sions of EVI1, SUMO1 and actin as loading control are shown in the
right panel. Thus, negative regulation imposed by sumoylated EVI1 on
Bcl-xL promoter is due to the decrease in DNA binding of EVI1 in the
presence of SUMO1. Non-sumoylated EVI1 indeed exhibits higher tran-
scriptional activity compared to its sumoylated counterpart, correlating
with its enhanced binding to the Bcl-xL promoter.
3.5. PIASy enhances sumoylation of EVI1 and regulates its function
SUMO E3 ligases function to promote the efﬁciency and substrate
speciﬁcity of sumoylation. SUMO E3 ligases include the protein
inhibitor of activated STAT family proteins (PIAS, which include
Fig. 3. EVI1 and SUMO1 reside in nuclear speckles. (A) Indirect immunoﬂuorescence assay was performed in HEK293T cells transfected with CMV-ﬂag-EVI1 and
pCDNA3-SUMO1-HA, probed with anti-ﬂag/anti-HA antibodies and EVI1 positive SKOV3cells with anti-EVI1/anti-SUMO1 antibodies and its corresponding Alexa ﬂuor 488 and
594 secondary antibodies. Merged picture reﬂects co-localization of EVI1 and SUMO1 in nuclear speckles. The images represent reconstruction of 10 optical sections (Z stack)
obtained by confocal microscopy (Leica, Germany). Scatter plot data showed a signiﬁcant co-localization which is above 85% (panel 5) in both the cell line. P. C, Pearson's coefﬁcient;
C. R, co-localization rate. (B) Indirect immunoﬂuorescence assay were performed in HEK293T cells co-transfected with CMV-ﬂag-EVI1 (3KR) with pCDNA3-SUMO1-HA by anti-ﬂag/
anti-HA antibodies and corresponding Alexa ﬂuor 488 and 594 secondary antibodies. The images represent 10 optical sections (Z stack) reconstructed and obtained from confocal
microscopy. Scatter plot data reﬂects the co-localization rate (C. R) and Pearson's coefﬁcient (P. C) of EVI1 (3KR) with SUMO1. 630× (63× ∗ 10×) magniﬁcation was used for cap-
turing all the images with confocal microscopy.
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Pc2, and Ran binding protein 2 (RanBP2) [36]. PIAS proteins regulate
the transcriptional activity of several proteins through different
mechanisms [37,38]. To this end we found that EVI1 interacts
with PIASy by co-immunoprecipitation assay. HEK293T cells
transfected with EVI1-myc and PIASy-ﬂag showed that PIASy efﬁ-
ciently co-immunoprecipitated with EVI1 protein (Fig. 5A, panel 1,
lane 3). We also found that EVI1 interacts with PIASy by reverse
co-immunoprecipitation i.e. immunoprecipitated with anti-ﬂag
(PIASy) and western blotting with anti-EVI1 antibody (Fig. 5A,
panel 3, lane 3). Panels 2 and 4 show the immunoprecipitated EVI1
and PIASy proteins and panels 5 and 6 depict the input cell lysates.
As PIAS protein family acts as SUMO ligase and helps in recruiting
SUMO to target proteins, we checked whether PIASy has any role in
EVI1 sumoylation. There was a comparatively more intense slow mi-
grating band (indicated by an arrow) observed when EVI1-ﬂag was
co-transfected with PIASy-ﬂag, SUMO1-HA and Ubc9-ﬂag (Fig. 5B,
lane 3) in comparison to EVI1-ﬂag co-transfected with SUMO1-HA
and Ubc9-ﬂag (Fig. 5B, lane 2). Lower panels showed the expression
of SUMO1, Ubc9 and PIASy. To check the functional relevance of the in-
teraction between EVI1 and PIASy, reporter gene assay was performed
which revealed that PIASy when co-expressed with EVI1 repressed
the activity of EVI1 on Bcl-xL promoter (Fig. 5C, bar 4). Since, SUMO1
and PIASy both had a negative effect on EVI1 transcriptional activity;
we checked the extent of negative regulation of PIASy and SUMO1 onEVI1 activity. There was an enhanced impairment in promoter activity
when PIASy and SUMO1 were co-transfected with EVI1 in comparison
to only EVI1 (Fig. 5C, bar 5 and 2). Thus our data shows that PIASy can
affect EVI1 activity both in presence or absence of SUMO1. In order to
further elucidatewhether PIASy as a SUMO ligase is promoting the neg-
ative regulation of EVI1 or it is a sumoylation independent function we
performed reporter gene assay by co-transfecting Bcl-xL promoter con-
struct and PIASy-ﬂag with EVI1-ﬂag and EVI1(3KR)-ﬂag. The luciferase
activity showed that PIASy negatively regulated EVI1 (3KR) (Fig. 5D, bar
5) similar to wild type EVI1 (Fig. 5D, bar 3) which suggest that PIASy is
not only a SUMO ligase for EVI1, but also acts as an interacting partner
which regulates EVI1 independent of its SUMO ligase activity. The pro-
tein expressions of EVI1, EVI1 (3KR), SUMO1 and PIASy for reporter
gene assays in Fig. 5C and D are shown through western blotting and
depicted below the bar diagrams.
3.6. Arsenic enhances SUMO conjugation of EVI1 and negatively regulates
Bcl-xL expression
ATO treatment iswell studied for curing APL, inwhich arsenic induces
the formation of PML bodies through SUMOmodiﬁcation which leads to
the degradation of PML and PML/RARα fusion protein. SKOV3 cells treat-
ed with 1 μM ATO for 1 h were lysed and subjected to immunoblotting
with anti-EVI1 antibody. We found that the modiﬁed form of EVI1 was
enhanced after 1 h of ATO treatment to SKOV3 cells (Fig. 6A, lane 2,
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dle panel). Also arsenic exposure enhanced EVI1–SUMO1 co-localization
to large nuclear bodies (Fig. 6B). It was strongly suggested that ATO me-
diated PML sumoylation was found to be critical for PML targeting onto
the nuclear bodies and recruitment of NB-associated proteins, which in
turn contribute to apoptosis induction or transcriptional regulation
[39–41]. Co-localization study of EVI1 and PML in SKOV3 cells after 1 h
of ATO treatment revealed that ATO treatment didn't recruit EVI1 to
PML bodies (Fig. 6C) which suggests that EVI1 mediated functions or itsFig. 4. Sumoylation negatively regulates EVI1 mediated transcriptional activation and DNA
moter plasmid pGL2-Bcl-xL/pGL4.10-SIRT1 promoter and pRL-TK (internal control) togeth
tions. After 24 h cells were lysed and luciferase activity was measured with luminometer
were analyzed by immunoblotting with anti-EVI1/anti-HA antibodies. Statistical signiﬁcance
P value b0.01 (**) for EVI1 compared with EVI1 + SUMO1 in subpanel A; P value b0.001 (**
assay performed by silencing endogenous SUMO1 in HEK293T cells to assess the activity of E
analyzed by immunoblot with anti-EVI1/anti-SUMO1 antibodies. P value b0.05 (*) for EV
transfected with CMV-ﬂag-NLS, CMV-ﬂag-EVI1/CMV-ﬂag-EVI1 (3KR) with or without p
pRL-TK were lysed after 24 h and luciferase activity was measured. Expression levels of E
P value b0.01 (**) for EVI1 compared with vector and EVI1 + SUMO1 compared with EVI
Su Ub (SUMO–Ubc9 fusion plasmid) and CMV-ﬂag-EVI1 with Su Ub (SUMO–Ubc9 fusion pl
was performed. Western blotting with anti-EVI1 and anti-SUMO1 shows the expression o
transfected with control-siRNA or SUMO1-siRNA was subjected to ChIP, real time PCR and
samples. (H) RQ-PCR was performed with RNA isolated from SKOV3 cells transfected with c
were used for normalization. Statistical signiﬁcance was assessed by unpaired t-test; P value
with SUMO1-siRNA. The expression of EVI1, Bcl-xL, and SUMO1 in control-siRNA and SUMO1
Actin is taken as loading control.degradation is not directly related to PML nuclear bodies. As sumoylation
negatively regulated EVI1 mediated transactivation of Bcl-xL promoter,
immunoblotting assay performed with the lysates of SKOV3 cells treated
with 1 μMATO for 1 h showed a decrease in Bcl-xL protein expression in
comparison to untreated SKOV3 cells (Fig. 6D, upper panel). Lower panel
depicts the ratio of densitometric analysis of Bcl-xL and actin proteins
plotted in graphical form. Thus, there are possibilities that the decrease
in the Bcl-xL protein expression may be an effect imposed by enhanced
sumoylated form of EVI1.binding activity. (A–B) HEK293T cells were transiently transfected with luciferase pro-
er with CMV-ﬂag-NLS, CMV-ﬂag-EVI1 and pCDNA3-SUMO1-HA in different combina-
(GLOMAX 20/20, Promega, USA). Expression levels of transfected EVI1 and SUMO1
was assessed by one way ANOVA; P value b0.001 (***) for EVI1 compared with vector,
*) for EVI1 compared with vector and EVI1 + SUMO1 in subpanel B. (C) Reporter gene
VI1 on Bcl-xL promoter. Expression levels of transfected EVI1 and silenced SUMO1 were
I1 with control siRNA compared to EVI1 with SUMO1-siRNA. (D–E) HEK293T cells
CNDA3-SUMO1-HA along with pGL2-Bcl-xL/pGL4.10-SIRT1 promoter construct and
VI1 and SUMO1 were checked by immunoblotting with anti-EVI1/anti-HA antibodies.
1 (3KR) + SUMO1. (F) HEK293T cells transfected with CMV-ﬂag-NLS, CMV-ﬂag-EVI1,
asmid) was processed for ChIP assay with anti-EVI1 antibody. PCR for Bcl-xL promoter
f EVI1 and Su Ub (SUMO–Ubc9 fusion protein) proteins. (G) Same set of SKOV3 cells
immunoblotting. ChIP PCR for Bcl-xL promoter was performed with input and eluted
ontrol-siRNA or SUMO1-siRNA to check the relative Bcl-xL mRNA level. β-actin primers
b0.01 (**) for SKOV3 cells transfected with control-siRNA compared to cells transfected
-siRNA transfected with SKOV3 cells for ChIP and RQ-PCR is shown by western blotting.
Fig. 4 (continued).
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Fig. 5. PIASy interacts with and enhances EVI1 sumoylation. (A) HEK293T cells were transfected with EVI1-myc, PIASy-ﬂag and EVI1-myc together with PIASy-ﬂag. Cells were lysed
and immunoprecipitated with anti-EVI1/anti-ﬂag antibodies followed by western blotting. (B) HEK293T cells were transfected with only CMV-ﬂag-EVI1 or CMV-ﬂag-EVI1 with
SUMO1-HA, CMV-Ubc9-ﬂag and with or without PIASy-ﬂag. After 36 h cells were lysed and subjected to immunoblotting with anti-ﬂag and anti-HA antibodies. (C–D) HEK293T
cells were transfected with pGL-2-Bcl-xL promoter construct, pRL-TK in different combination with CMV-ﬂag-NLS, CMV-ﬂag-EVI1/CMV-ﬂag-EVI1 (3KR), PIASy-ﬂag and
SUMO1-HA. After 24 h of transfection cells were lysed and luciferase activity was measured. Protein expression for the transfected plasmids was checked by immunoblotting
with anti-EVI1, anti-ﬂag and anti-HA antibodies. Statistical signiﬁcance was assessed by one way ANOVA; P value b0.001(***) for EVI1 compared with vector and EVI1 compared
with EVI1 + SUMO1 + PIASy in subpanel C; P value b0.01 (**) for EVI1 (3KR) compared with EVI1 (3KR) + PIASy in subpanel D. All the results represent the mean ± s.e. of ex-
periments performed in triplicates.
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Fig. 6. ATO enhances sumoylation and co-localization of EVI1 with SUMO1. (A) SKOV3 cells treated with 1 μM of ATO for 1 h were subjected to immunoblotting with anti-EVI1 and
anti-SUMO1 antibodies. Arrow shows the sumoylated band of EVI1. Actin is taken as loading control. (B) Indirect immunoﬂuorescence assay was performed in untreated and ATO
(1 μM, 1 h) treated SKOV3 cells with anti-EVI1/anti-SUMO1 antibodies and its corresponding Alexa ﬂuor-488 and 594 secondary antibodies. The images were obtained by confocal
microscopy. The magniﬁcation used for capturing the images is 630× (63× ∗ 10×). (C) Indirect immunoﬂuorescence assay performed in untreated and ATO (1 μM, 1 h) treated
SKOV3 cells with anti-EVI1/anti-PML antibodies and its corresponding Alexa ﬂuor-488 and 594 secondary antibodies. The images were obtained by confocal microscopy. The mag-
niﬁcations used for capturing the images are 1000× (100× ∗ 10×) for upper panel and 630× (63× ∗ 10×) for lower panel. (D) ATO treated SKOV3 cells were lysed and immuno-
blotting was performed with anti-Bcl-xL antibody. Actin expression is taken as loading control. Bar diagram shows the graphical representation of western blotting by densitometric
analysis. Error bar represents ± s.e., asterisk (**) indicates P value b0.01 obtained by t-test.
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For proper functioning of cellular pathways and to dictate biological
functions a ﬁne tuning of the protein is strictly required. Several covalent
modiﬁers involved in controlling various cellular processes can offer a
simple way to control the activity that can eventually regulate or deregu-
late protein functions. Sumoylation is one of the modiﬁcations which
have emerged as an important module regulating the function of various
proteins. EVI1 consists of activation/repression domain present in be-
tween two sets of DNA binding domain which activates as well as re-
presses several downstream targets. Bcl-xL, SIRT1, PLZF, GATA-2 are
activated by EVI1 whereas calreticulin and PTEN were found to be re-
pressed [24,26,42–45]. Aberrant function of EVI1 imposed on down-
stream targets is related to several forms of leukemia and other
disorders. Thus, unveiling the role of sumoylation on EVI1 transcriptional
activitymay help to understand the basic biology of the protein. The pres-
ent study demonstrates that EVI1 is sumoylated at lysine residues 533,
698 & 874 and modiﬁcation of the sites can abrogate EVI1 sumoylation.
SUMOmodiﬁcation iswell known for regulating sub-cellular distribu-
tion and nuclear trafﬁcking of proteins and is associated with nuclear
speckles which are known to be hot spots for functionally active proteins[32,46]. It is already known that PML requires sumoylation for its nuclear
body formation which is disrupted in acute promyelocytic leukemia
[47,48]. Confocal imaging revealed that EVI1 was co-localized with
SUMO1. However, co-localizationwas disruptedwhen the lysine residues
that underwent sumoylation were modiﬁed to arginine. This shows that
like acetylation, sumoylation is indispensible for discrete cellular localiza-
tion and also plays a role in regulating the function of EVI1 by controlling
translocation from diffused to speckle pattern within the nucleus.
Bcl-xL was found to be activated by EVI1. Alteration in the cellular
level of pro and anti-apoptotic Bcl-2 family proteins is related to tumori-
genesis in both transgenicmodels and clinical cases [49]. As inmost of the
cases sumoylation acts as a repressor command for the protein, we ob-
served the same phenomenon with EVI1. Sumoylated EVI1 signiﬁcantly
impaired Bcl-xL promoter activity, whereas when the sumoylation sites
were mutated or SUMO1 was silenced, the EVI1 mediated activation
was restored. Thus the results obtained clearly show that sumoylated
form of EVI1 affects the extent of activation imposed by unmodiﬁed
EVI1. Reporter gene assay performed with sumoylation mutants showed
that the three putative sumoylation sites found in EVI1 are important for
the proper functioning of EVI1 protein in the cellular system. In several
proteins like SOX2, TEL sumoylation affects the DNA binding ability of
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data also shows that sumoylation decreased the DNA binding ability of
EVI1 which may be a possible reason for negative regulation of
sumoylation on EVI1 function. As the sumoylation sites were found in re-
pression domain and acidic domain and not in DNA binding domain, it is
likely that sumoylation causes some conformational changes in EVI1, as
found in thymine DNA glycosylase (TDG) which affects its DNA binding
ability [50]. Itmay be possible that by recruitingHDAC or bringing confor-
mational changes, sumoylated EVI1 can favor transcriptional repression.
It was shown earlier that EVI1 regulates apoptosis by activating Bcl-xL,
an anti-apoptotic gene, and the effect is impaired by acetylation. Regula-
tion of apoptosis is a reﬂection of the changes in the level of pro and
anti-apoptotic genes. Since sumoylation regulates the EVI1 mediated ac-
tivity on Bcl-xL, we hypothesize that sumoylation can regulate apoptosis
by regulating EVI1.
Taking SUMO ligases into consideration, in context of enhancement
of EVI1 sumoylation we found PIASy to be a new interacting partner
which not only interacts with EVI1 but also enhanced its sumoylation.
Although PIASy acted as a ligase and enhanced sumoylation of EVI1,
the major limiting factor for modiﬁcation to occur was SUMO1. Our
data also revealed that PIASy itself negatively regulated EVI1 mediated
transactivation both with and without SUMO1. We showed that PIASy
efﬁciently repressed the transcriptional activity of mutant form similar
to wild type EVI1, which implies that the negative regulation imposed
by PIASy is independent of its ligase function. Thus like LEF1[51], we
found the dual regulatory role of PIASy, ﬁrst, by acting as a SUMO ligase
and enhancing EVI1 sumoylation; and second as a co-regulator inde-
pendent of its ligase activity.
ATO affects cells through various mechanisms, inﬂuencing several
pathwayswhich results in vast range of cellular processes like apoptosis
induction, angiogenesis inhibition, autophagy and growth inhibition.
The response varies fromone cell type to the other. ATO is known to tar-
get AME (AML1/MDS1/EVI1) via MDS1 and EVI1 and degrades EVI1
through ubiquitin–proteosomal pathway [52]. Three out of ﬁve MDS
patients with high EVI1 expression showed a good response when
treated with ATO and thalidomide [53]. We found that ATO treatment
not only enhanced sumoylated EVI1 but also drives nucleoplasmic frac-
tion of EVI1 to large nuclear dots distinct from PML bodieswith SUMO1.
As Bcl-xL downregulation was also observed after ATO treatment, it
shows that depending on the ratio of modiﬁed and unmodiﬁed form
of EVI1 in the cellular pool the cells' fate is determined.
4.1. Conclusion
Various protein modiﬁcation and cellular pathways deregulate the
cell which leads to neoplastic transformation. Despite its role in several
solid tumors and hematopoietic malignancies, the regulators that
govern the function of EVI1 are partially known. Our study for the
ﬁrst time shows that EVI1 is post-translationally modiﬁed by SUMO1
which negatively regulates the function of EVI1. Present study suggests
that unmodiﬁed form of EVI1 protects cells from apoptosis whereas its
sumoylated counterpart signiﬁcantly impairs the activation imposed by
EVI1 on Bcl-xL which may interfere with the EVI1 mediated regulation
of apoptosis. Thus, the study revealed sumoylation as a new regulator
of EVI1 and shows that the sumoylated and desumoylated form of
EVI1 behave differently in their transcriptional activity. It will be inter-
esting to further understand the role of sumoylated/desumoylated EVI1
in context of cellular transformation.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.06.003.
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